Molecular Partners AG (NASDAQ:MOLN – Get Rating) – Equities researchers at SVB Leerink upped their FY2022 EPS estimates for Molecular Partners in a research note issued to investors on Wednesday, November 23rd. SVB Leerink analyst D. Graybosch now forecasts that the company will earn $4.01 per share for the year, up from their prior estimate of $3.79. SVB Leerink currently has a “Market Perform” rating and a $8.00 target price on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is $3.52 per share.
Molecular Partners (NASDAQ:MOLN – Get Rating) last released its earnings results on Thursday, October 27th. The company reported ($0.42) earnings per share for the quarter. The company had revenue of $2.45 million for the quarter.
Molecular Partners Stock Performance
Shares of MOLN opened at $6.69 on Thursday. The company has a 50-day moving average price of $6.38 and a two-hundred day moving average price of $6.57. Molecular Partners has a 12 month low of $5.50 and a 12 month high of $32.04.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Federated Hermes Inc. boosted its holdings in Molecular Partners by 94.2% in the 1st quarter. Federated Hermes Inc. now owns 457,037 shares of the company’s stock valued at $9,264,000 after purchasing an additional 221,743 shares during the period. Tang Capital Management LLC acquired a new position in Molecular Partners during the 3rd quarter worth approximately $105,000. Finally, AlphaCentric Advisors LLC acquired a new position in Molecular Partners during the 3rd quarter worth approximately $218,000. 2.70% of the stock is currently owned by institutional investors and hedge funds.
About Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.